Clinical Trials Logo

Filter by:
NCT ID: NCT06267924 Enrolling by invitation - Vestibular Migraine Clinical Trials

SENSE-VM: Safety and Effectiveness of a Novel Medical Device for Symptom Ease in Vestibular Migraines

Start date: February 28, 2024
Phase: N/A
Study type: Interventional

The goal of this virtual clinical trial is to compare the effectiveness of two study devices in providing temporary relief to adults aged 18-75 who suffer from symptoms of chronic Vestibular Migraines (VM), also known as Migraine Associated Vertigo. Participants will be: - Enrolled up to 50 days; enrollment, 14 days in Baseline Phase (no device), 7 days in Transition Phase, 28 days in Treatment Phase (study device) - Randomized and stratified into groups based on the referring clinic to be assigned one study device - Asked to use the study device as instructed by the study coordinator - Asked to submit daily diaries reporting their symptoms and use of device, and to participate in tele-health visits with study coordinators - Asked to provide their vertigo diagnosis from their physician - Compensated for their participation Researchers will compare the randomized groups to determine which group responds better to which device.

NCT ID: NCT06267872 Not yet recruiting - HIV Clinical Trials

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

Start date: June 14, 2024
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, phase 1 clinical trial to test two human immunodeficiency virus (HIV) vaccines with two adjuvants. An adjuvant is an ingredient used with some vaccines that may help people make an immune response. HIV is the virus that causes acquired immunodeficiency syndrome (AIDS). About 42 people will take part in the HVTN 309 clinical trial. This clinical trial will take place at multiple sites in the US and South Africa and the clinical trial is divided into 3 parts: Part A, Part B and Part C. About 3 people will participate in Part A of this study. After results from Part A are reviewed, it will be determined whether or not Part B and Part C of the clinical trial will proceed.

NCT ID: NCT06267846 Recruiting - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Start date: March 20, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).

NCT ID: NCT06267729 Recruiting - Clinical trials for Metastatic Prostate Cancer

Study of AZD0754 in Participants With Metastatic Prostate Cancer

APOLLO
Start date: March 12, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.

NCT ID: NCT06267547 Recruiting - Physical Activity Clinical Trials

Healthy Activities Improve Lives (HAIL)

HAIL
Start date: April 23, 2024
Phase: N/A
Study type: Interventional

The investigators have developed an online platform to support the 8-week, F&S! exercise program called the Healthy Activity Improves Lives (HAIL) online platform. The aim of this study is to perform a cluster randomization of four racially diverse churches or senior centers to either the standard F&S! program, or the combined HAIL Online Platform + F&S! program to examine the efficacy of the HAIL online platform + F&S! program for older adults in black communities.

NCT ID: NCT06267521 Recruiting - Clinical trials for Emotional Regulation

The STRENGTHEN Study

Start date: March 6, 2024
Phase: N/A
Study type: Interventional

This study uses two different types of interventions including electrical brain stimulation delivered during sleep, and brief, daily meditation training. The investigators are trying to figure out whether these techniques, either alone or in combination with each other, can positively impact the brain networks that support our ability to think flexibly and to regulate our emotions. 48 participants will be enrolled and can expect to be on study for up to 9 months.

NCT ID: NCT06267365 Recruiting - Clinical trials for Chronic Pancreatitis

Predictive Biomarker for Endoscopic Therapy in Chronic Pancreatitis

Start date: November 27, 2023
Phase:
Study type: Observational

This is an observational prospective study to develop predictive biomarkers for pain response in participants with chronic pancreatitis scheduled for endoscopic therapy. Participants will undergo baseline assessments including electroencephalography (EEG), quantitative sensory testing (QST), and psychosocial questionnaires. Response to endoscopic therapy will be assessed at approximately 3, 6, 12 and 18 months post-procedure using questionnaires.

NCT ID: NCT06267339 Not yet recruiting - Children Clinical Trials

Effects of Transcranial Random Noise Stimulation on Motor Learning in Typically Developing Adolescents

Start date: September 1, 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this study is to compare motor learning rates on two different tasks, when combined with non-invasive brain stimulation.

NCT ID: NCT06267313 Recruiting - Anxiety Clinical Trials

Attention Training for COVID-19 Related Distress

Start date: February 19, 2024
Phase: N/A
Study type: Interventional

The study aims to test whether attention training (attention bias modification or attention control training) reduces distress or COVID-19 related anxiety compared to a neutral condition.

NCT ID: NCT06267274 Not yet recruiting - Ocular Hypertension Clinical Trials

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study